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The isolation of a novel biologically active peptide, designated galanin, is described. The peptide was 
discovered by the detection of its C-terminal amide structure in porcine intestinal extract using a chemical 
method. It was found that galanin consists of 29 amino acids and the complete amino acid sequence is: 
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg- 
Ser-Phe-His-Asp-Lys-Tyr-Gly-Leu-Ala-NHZ. Galanin was found to contract smooth muscle 
preparations from the rat and to cause a mild and sustained hyperglycemia in dog. 
Gastrointestinal polypeptide Amino acid sequence C-terminal amide Biological activity 
1. INTRODUCTION 
Many biologically active peptides contain a C- 
terminal amidated structure [ 1,2]. Peptides with 
such a structure may be assayed by using a chemi- 
cal technique in which the C-terminal of the peptide 
is cleaved off by a proteolytic enzyme, converted 
into the dansyl derivative, extracted selectively and 
identified by thin-layer chromatography [3]. Using 
this chemical technique, it was found that extracts 
of porcine intestine and brain contain many pre- 
viously unknown peptides with the C-terminal 
amidated structure [3,4]. Efforts to isolate and 
identify some of these peptide amides have resulted 
in the finding of previously unknown peptides, 
peptide HI (PHI) [4,5], peptide YY (PYY) [4,6] 
and neuropeptide Y (NPY) [7,8]. Subsequent 
studies indicated that these peptides may be hor- 
monal and neural peptides 191. These results there- 
fore suggest that new hormonal and neural peptides 
may be found by a systematic search for peptide 
amides from tissue extracts using the chemical 
assay technique. 
During the study of purification of PHI and 
PYY, it was noticed that extracts of porcine intes- 
tine contained a peptide with C-terminal alanine 
amide. We report here the isolation, amino acid se- 
quence and some of the biological activities of this 
novel peptide amide which we have designated 
galanin from the N- and C-terminal residues, gly- 
tine and alanine. 
2. MATERIALS AND METHODS 
Alanine amide was obtained from Vega Bio- 
chemicals and dansyl alanine amide was prepared 
from alanine amide by reaction with dansyl 
chloride [lo]. Reagents for sequence analysis were 
of sequanal grade and acetonitrile was of HPLC 
grade. Other reagents were of analytical grade. 
Polyamide thin layer sheets were obtained from 
Schleicher & Schtill, thermolysin (EC 3.4.24.4) 
from Daiwa Kasei K.K., Osaka, and trypsin 
(EC 3.4.21.4; L-1-tosylamide-2-phenylethyl chloro- 
methyl ketone-treated) from Worthington Bio- 
chemical Co. 
Galanin was determined by the amount of alanine 
amide released after treatment of the sample with 
thermolysin in a chemical assay method [3]. 
Reversed-phased high performance liquid chroma- 
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tography (HPLC) was performed in a Waters in- 
strument using a PBondapak C-18 column under 
conditions described in the legends to fig.2,3. N- 
terminal amino acids were determined as in [lo] by 
using dansyl chloride. Amino acid compositions 
were determined with a Beckman 121 M automatic 
amino acid analyzer after hydrolysis of samples in 
5.7 M HC1/0.5% phenol at 110°C for 24 h. The 
tryptophan content was determined after hydrolysis 
in 3 M mercaptoethanesulfonic acid [ 111. Liquid- 
phase sequencer degradation was performed in a 
Beckman 890D instrument, in the presence of 
glycine, precycled polybrene using a 0.1 M quadrol 
peptide program [ 121. Phenylthiohydantoin amino 
acids were determined by HPLC [ 131 and thin- 
layer chromatography (141. Manual sequence ana- 
lysis was performed by a modified dansyl-Edman 
method [S]. 
Biological actions of galanin was tested on a 
fundus strip, ileum, proximal colon and urinary 
bladder from rat. The isolated tissues were pre- 
pared as in [ 151. The tissues, obtained from non- 
fasted and decapitated animals, were immediately 
suspended in a siliconized organ bath which con- 
tained a modified Krebs-Henseleit solution (5 ml) 
with glucose 2 g/l. The solution was bubbled with 
95% 02 and 5% CO2 at 37°C. The tissues were 
allowed to equilibrate for about 40 min and regular 
contractions were elicited by acetylcholine (Roche) 
before the experiments. Dose intervals for galanin 
were at least 10min. The contractions of the rat 
urinary bladder were registered using a Harvard 
isotonic force transducer (no. 385) and the contrac- 
tions of the other organs were registered using a 
Grass isometric force transducer FT03C. The 
twitches were expressed in mN except for the rat 
urinary bladder where the twitches were measured 
in mm. The effect of galanin on plasma glucose 
levels was studied using conscious dogs as in [16]. 
3. RESULTS 
3.1. Isolation procedures 
Galanin was purified from a side fraction ob- 
tained during the isolation of PYY. Briefly, procine 
upper intestines (4000 kg) were boiled in water for 
lOmin, frozen, minced and extracted with 0.5 M 
acetic acid for 24 h. Peptides in the extract were 
adsorbed onto alginic acid, eluted with 0.2 M HCl 
and precipitated with NaCl at saturation. They 
FRACTION NUMBER 
Fig. 1. Ion exchange chromatography of the starting ma- 
terial on CM cellulose (1.6 x 15 cm) in 0.02 M NH4HCO3 
(pH 8) at a flow rate of 0.55 ml/min. Fractions (5 ml) 
were lyophilized and an aliquot from each was subjected 
to the chemical ssay, the shaded area indicates fractions 
containing alanin. 
were further purified by extraction with 66% etha- 
nol, gel chromatography on Sephadex G-25 and 
extraction with methanol. The methanol-soluble 
fraction was subjected to chromatography on a 
CM-cellulose column. It was first eluted with 
0.02M NI%HC03 (adjusted to pH6.5 by COz) 
and then with 0.2 M NH4HCOs (pH 8). The frac- 
tion eluted with 0.2 M NH4HCO3 was further puri- 
fied by gel chromatography on Sephadex G-25 [6]. 
The fractions (starting material 125 mg) containing 
PYY and galanin were purified further by rechro- 
matography on CM cellulose in 0.02 M NH4HCO3 
(pH 8) as shown in fig.1. Fractions 11-14 con- 
tained galanin and were pooled and lyophilized. 
The preparation (18 mg) was further purified by 
reversed-phase HPLC on p Bondapak C- 18 (fig.2). 
This step yielded a preparation (2.5 mg) found to 
be homogeneous as judged by TLC, HPLC, deter- 
mination of N-terminal residue and amino acid 
analysis. 
3.2. Structural studies 
The results of amino acid analysis suggested that 
the peptide consisted of 29 amino acid residues as 
shown in table 1. Analyses for the terminal groups 
revealed that it had N-terminal alanine amide. The 
name galanin was given to this peptide based on its 
N- and C-terminal amino acids (glycine and ala- 
nine). Treatment of galanin with trypsin yielded 
four fragments (T-l to T-4) which were separated 
125 
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Fig.2. Reversed-phase HPLC separation of fractions 
11-14 from fig.1. An aliquot (3 mg) of the fraction 
(18 mg) was applied to apBondapak C-18,7.8 x 300mm 
column and isocratically eluted with 35% ethanol/5 mM 
N&OAc/0.2% HOAc at a flow rate of 2 ml/min. The 
major peak (oblique lines) contained galanin. 
ELUTION VOLUME (ml) 
by HPLC (fig.3). The complete amino acid se- 
quences of T-2-T-4 were determined by a manual 
sequence analysis as shown in fig.4. These results, 
together with the results from the amino acid 
analyses (table 1) indicate that one of the frag- 
ments, T-4, is composed of T-2 and T-3 fragments 
and produced because of a slow hydrolysis at a 
Lys-Tyr bond (position 25-26). The whole mole- 
cule of galanin (20 nmol) was subjected to Edman 
degradation in a Beckman 890D liquid-phase se- 
quencer which revealed the amino acid sequence 
up to residue 28 and traces of the last residue. The 
repetitive yield was 96% and an initial coupling 
75%. From these results the complete amino acid 
sequence of galanin is deduced to be as in fig.4. 
3.3. Biological studies 
Galanin induced dose-dependent contractions of 
the fundus strip, ileum, colon and urinary bladder 
from the rat at concentrations above 20ng/ml 
(fig.5). Data indicate that the rate ileum may be a 
suitable bioassay organ for galanin. 
The effect of galanin on plasma glucose levels 
was also tested in dogs. Four dogs, conscious and 
overnight fasted, received 2 h peripheral vein in- 
fusions of galanin at a dose of 2kg* kg-‘. h- ’ 
which produced no evidence of distress or discom- 
Table 1 
Amino acid compositions of galanin and its isolated tryptic fragments 
Amino acid Galanin T-l T-2 T-3 T-4 
Ala 3.1 (3) 2.0 (2) 1.0 (1) 1.0 (1) 
Arg 1.1 (1) 0.9 (1) 
Asx 4.0 (4) 2.9 (3) 1.0 (1) 1.1 (1) 
Gly 4.0 (4) 3.0 (3) 1.0 (1) 1.1 (1) 
His 3.0 (3) 2.2 (2) 1.0 (1) 1.1 (1) 
Be 1.1 (1) 0.9 (1) 
Leu 4.1 (4) 3.0 (3) 0.9 (1) 0.9 (1) 
LYS 1.0 (1) 1.1 (1) 1.1 (1) 
Phe 1.0 (1) 0.9 (1) 1.0 (1) 
Pro 1.0 (1) 1.1 (1) 
Ser 2.0 (2) 0.8 (1) 1.0 (1) 0.8 (1) 
Thr 1.0 (1) 0.9 (1) 
Trp 0.7 (1) 0.7 (1) 
Tyr 2.1 (2) 1.0 (1) 1.0 (1) 1.1 (1) 
Sum 
N-terminus 
29 
Gly 
20 
Gly 
5 
Ser 
4 
T yr 
9 
Ser 
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Fig.3. HPLC separation of tryptic fragments of galanin 
(T-l to T-4). Galanin (70rg) was treated with trypsin 
(3pg) in 35~1 of 1% NH4HCO3 for 1 h at room tem- 
perature. The lyophilized digest was applied to a 
PBondapak C-18 column (3.9 x 300nm) and separated 
at a flow rate of 1 ml/min by using a linear gradient 
system of 0.12% CF3COOH/HzO (solvent A) and 0.1% 
CF,COOH/CH3CN (solvent B, O-50070). 
fort. During the infusions, plasma glucose levels 
gradually increased becoming statistically signifi- 
cantly (Student’s t-test) elevated from basal values 
at 20 min after initiation of infusion and attaining 
plateau values at 60 min which were then sustained 
during the remainder of the infusion (table 2). On 
cessation of the infusion, plasma glucose levels 
gradually fell and reattained basal values 40 min 
post-infusion. Hence, intravenous infusions of 
galanin result in a mild (but statistically signifi- 
cant) sustained hyperglycemia. 
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Fig.5. Responses of isolated rat fundus strip, rat ileum, 
rat proximal colon and rat urinary bladder to galanin 
(20 ng.ml-’ and higher concentrations as indicated). 
Arrow below the registration shows the time for ad- 
ministration of galanin and the triangle (v) above the 
curve shows the time for washing. 
Table 2 
Effect of galanin on plasma glucose levels 
Time (min) Plasma glucose level 
(mean + SEM, mg*dl-‘) 
Basal 107.9 * 4.5 
20 118.1 * 6.4 (p< 0.05) 
60 134.0 f 9.5 (p < 0.02) 
90 134.0 * 7.7 (p < 0.01) 
120 130.5 f 9.5 (p < 0.01) 
16 17 18 19 20 21 22 23 24 25 26 27 28 29 
Ile-Asg-Asn-Hls-Arg-Ser-Phe-H,s-Asp-Lys-Tyr-Gly-Leu-Ala-NH2 
* - T-2 A - T-3 - 
T-4 
Fig.4. The complete amino acid sequence of galanin. 
T-l to T-4, tryptic fragments. 
4. DISCUSSION 
The C-terminal tetrapeptide amide of galanin, 
-Tyr-Gly-Leu-Ala-NHz, is structurally similar 
to the corresponding part of physalaemin, -TX- 
%-Leu-Met-NH2 [17] and substance P, -Phe- 
G&-Leu-Met-NH2 [18] and to the sequence of 
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gonadoliberin, Glp-His-Trp-Ser-B-Gly-Leu- 
Arg- Pro-Gly-NH2 [19]. No structural similarities 
were found between galanin and corticotropin- 
releasing factor [20] in spite of the fact that 
both peptides contain the C-terminal alanine 
amide. Galanin contains the N-terminal sequence, 
G&-Trp-Thr-Leu-Asn-s, similar to that of 
propiomelanocortin, Gly-Trp-Cys-Leu-Glu-Ser- - 
[21]. Furthermore, a middle part, -Gly-Tyr-Leu- 
Leu-Gly- appears similar to that of the phosphate 
acceptor peptide, -Gly-m-Ser-Leu-Gly- [22]. - 
Despite these partial similarities, however, the 
amino acid sequence of galanin is not identical to 
any known peptides and galanin may belong to a 
hitherto unknown peptide family. The C-terminal 
structural similarities of galanin to other well- 
known neuropeptides uggest hat it may also be a 
novel neuropeptide, which is supported by prelimi- 
nary immunohistochemical findings (in prepara- 
tion). 
Galanin was found to contract isolated prepara- 
tions from rat fundus, ileum, colon and urinary 
bladder and to induce a mild and sustained hyper- 
glycemia. 
The results indicated that galanin is a novel 
mammalian gut peptide with various biological 
actions. Its physiological roles in the gastrointes- 
tinal tract and other organs, as well as in the cen- 
tral and peripheral nervous systems, remain to be 
determined. 
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